Putative Biomarkers for Prognosis, Epithelial-to-Mesenchymal Transition, and Drug Response in Cell Lines Representing Oral Squamous Cell Carcinoma Progression
Genes · 2025
DOI: 10.3390/genes16020209 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, 2025. Verfasst von Mohamad Z Hamoui und 3 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Sciences Program, Midwestern University, Downers Grove, IL 60515, USA. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Mouth Neoplasms, Biomarkers, Tumor, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Midwestern University.
Abstract (Originalsprache)
Background/Objectives: Oral squamous cell carcinoma (OSCC) is the most common form of head and neck cancer and accounts for over 50,000 new cancer cases annually in the United States. The survival rates are markedly different for localized OSCC versus metastatic disease, for which the five-year survival rate is only 39%. Depending on its pathology and stage at diagnosis, the treatment may involve surgery, radiation, targeted therapy, or conventional chemotherapy. However, there is an unmet need for reliable biomarkers to predict the treatment response or link therapeutic efficacy to tumor progression. We sought to assemble a panel of OSCC tumor progression biomarkers that correlated with the epithelial-to-mesenchymal transition (EMT) and the response to cytotoxic drugs.
Methods
We used four cell lines that represented the stepwise progression from normal oral mucosa to dysplastic, invasive, and metastatic OSCC lesions and performed a quantitative analysis via Western blot for putative markers. EMT phenotypes were assessed using wound healing migration assays. Live cell imaging was used to assess drug effectiveness over time.
Results
The expression of stratifin, a tumor suppressor gene, is inversely correlated with both tumor progression steps and the expression of the EMT marker N-cadherin. Conversely, the E-cadherin and fibronectin expression was markedly decreased in the advanced-stage OSCC lines. In addition, metastatic Detroit 562 cells exhibited resistance to cell death following docetaxel treatment and showed clear migratory behavior.
Conclusions
We describe a molecular signature of advanced and drug-resistant OSCC tumors which encompasses multiple markers, warranting further investigation to establish their utility in predicting clinical outcomes and guiding the treatment options for patients afflicted with oral cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biomedical Sciences Program, Midwestern University, Downers Grove, IL 60515, USA.
- Department of Pathology, Midwestern University, Downers Grove, IL 60515, USA.
- Department of Pharmacology, Midwestern University, Downers Grove, IL 60515, USA.
ORCID-Profile: Hilal Arnouk, Cai M Roberts
Förderung
- Midwestern University
Zitieren
APA
Hamoui, M. Z., Rizvi, S., Arnouk, H., & Roberts, C. M. (2025). Putative Biomarkers for Prognosis, Epithelial-to-Mesenchymal Transition, and Drug Response in Cell Lines Representing Oral Squamous Cell Carcinoma Progression. Genes. https://doi.org/10.3390/genes16020209
Vancouver
Hamoui MZ, Rizvi S, Arnouk H, Roberts CM. Putative Biomarkers for Prognosis, Epithelial-to-Mesenchymal Transition, and Drug Response in Cell Lines Representing Oral Squamous Cell Carcinoma Progression. Genes. 2025. doi:10.3390/genes16020209
BibTeX
@article{Hamoui2025,
author = {Hamoui, Mohamad Z and Rizvi, Shuaa and Arnouk, Hilal and Roberts, Cai M},
title = {Putative Biomarkers for Prognosis, Epithelial-to-Mesenchymal Transition, and Drug Response in Cell Lines Representing Oral Squamous Cell Carcinoma Progression},
journal = {Genes},
year = {2025},
doi = {10.3390/genes16020209}
}
EUVIMED